National Institute of Allergy and Infectious Diseases (NIAID): HIV Infections trials

The registry lists 728 HIV Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 9 are open to participants now and 104 have results posted.

Phase 1 327Phase 2 183Phase 3 57Phase 4 7No phase 195(a study in two phases counts in both)

Studies

Page 7 of 8. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected PatientsCompletedNCT00000861Not applicable
• A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3CompletedNCT00000859Not applicable
• Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other InfectionsCompletedNCT00000858
• A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3CompletedNCT00000857Phase 1
• A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.CompletedNCT00000855Not applicable
• A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy AdultsCompletedNCT00000853Phase 1
• A Pilot Study of Allogeneic Lymphocyte Transfer in HIV InfectionCompletedNCT00000852Not applicable
• Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected ChildrenCompletedNCT00000851Phase 2
• The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV TherapyCompletedNCT00000850Phase 2
• A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected ChildrenCompletedNCT00000849Phase 1
• The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One YearCompletedNCT00000848Phase 2
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult VolunteersCompletedNCT00000847Phase 1
• A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.CompletedNCT00000846Phase 1
• A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human SubjectsCompletedNCT00000845Phase 1
• A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3CompletedNCT00000844Not applicable
• A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More MonthsCompletedNCT00000841Phase 3
• A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNACompletedNCT00000840
• A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant WomenCompletedNCT00000839Phase 1
• Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or DidanosineCompletedNCT00000838Phase 2
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion VaccineWithdrawnNCT00000835
• A Phase I Study of Methotrexate for HIV InfectionCompletedNCT00000834Phase 1
• A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.CompletedNCT00000833Phase 1
• A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult VolunteersCompletedNCT00000832Phase 1
• Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI MonotherapyCompletedNCT00000831Phase 2
• Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.CompletedNCT00000830
• Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With ZidovudineCompletedNCT00000828
• A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected ChildrenCompletedNCT00000827Phase 1
• The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3CompletedNCT00000825Phase 2
• A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected PatientsTerminatedNCT00000824Not applicable
• A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T CellsCompletedNCT00000822Phase 1
• Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected PatientsCompletedNCT00000821Phase 1
• Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.CompletedNCT00000818Phase 1
• A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV DiseaseCompletedNCT00000814Phase 1
• A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult VolunteersCompletedNCT00000813Phase 1
• A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive ChildrenCompletedNCT00000811Phase 2
• Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)CompletedNCT00000810Phase 1
• Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected WomenWithdrawnNCT00000809Phase 1
• A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected MothersCompletedNCT00000808Phase 1
• A Phase I Randomized Dose/Formulation Comparison Study of SC-52151CompletedNCT00000806Phase 1
• A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)WithdrawnNCT00000804Not applicable
• A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination TherapyCompletedNCT00000803Phase 2
• Methadone Effects on Zidovudine (ZDV, AZT) DispositionCompletedNCT00000800Phase 1
• A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human SubjectsCompletedNCT00000798Phase 1
• Women's Interagency HIV Study (WIHS)Status unknownNCT00000797
• A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human SubjectsCompletedNCT00000795Phase 1
• A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV InfectionCompletedNCT00000793Phase 2
• A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected SubjectsCompletedNCT00000792Phase 1
• A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDVCompletedNCT00000791Phase 2
• Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV InfectionCompletedNCT00000790Phase 2
• A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV InfectionCompletedNCT00000789Phase 2
• Heterosexual HIV Transmission Study (HATS). Prospective Cohort StudyCompletedNCT00000787Not applicable
• Heterosexual HIV Transmission Study (HATS)CompletedNCT00000783
• A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)CompletedNCT00000781Phase 2
• A "Pre-Enrollment" Protocol for HIV-Infected AdolescentsCompletedNCT00000780
• A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3CompletedNCT00000779Phase 1
• Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)CompletedNCT00000777Phase 1
• A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)CompletedNCT00000775Phase 1
• A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected MothersCompletedNCT00000774Phase 1
• A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive IndividualsCompletedNCT00000772Phase 1
• A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and DidanosineCompletedNCT00000770Phase 2
• Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)CompletedNCT00000765Not applicable
• Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.CompletedNCT00000764Phase 1
• A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV InfectionCompletedNCT00000762Phase 1
• Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected ChildrenCompletedNCT00000761Phase 1
• A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV InfectionCompletedNCT00000760Phase 1
• A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160CompletedNCT00000757Phase 1
• Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3CompletedNCT00000756Phase 1
• A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3CompletedNCT00000755Phase 1
• A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3CompletedNCT00000754Phase 2
• A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddCCompletedNCT00000753Phase 1
• A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV InfectionCompletedNCT00000750Phase 3
• A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 MonthsCompletedNCT00000749Phase 1
• An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3CompletedNCT00000747Phase 2
• A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160CompletedNCT00000745Phase 1
• A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected PersonsCompletedNCT00000743Phase 1
• A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)CompletedNCT00000742Phase 1
• Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV InfectionCompletedNCT00000739Phase 1
• Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected IndividualsCompletedNCT00000736Phase 3
• A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARCCompletedNCT00000735Phase 1
• Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and ZidovudineCompletedNCT00000734Not applicable
• Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected PatientsCompletedNCT00000733Phase 1
• Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and ZidovudineCompletedNCT00000732Not applicable
• Evaluation of the Interaction Between Acetaminophen and ZidovudineCompletedNCT00000731Not applicable
• A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional DiseaseCompletedNCT00000729Phase 1
• Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency SyndromeCompletedNCT00000726Phase 1
• An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody PositiveCompletedNCT00000721Phase 1
• A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving ZidovudineCompletedNCT00000720Phase 3
• A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV DiseaseCompletedNCT00000719Not applicable
• A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARCCompletedNCT00000718Not applicable
• A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV InfectionCompletedNCT00000716Phase 2
• A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected SubjectsCompletedNCT00000713Phase 1
• Influence of Probenecid and Quinine on the Pharmacokinetics of AzidothymidineCompletedNCT00000706Not applicable
• Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With HemophiliaCompletedNCT00000705Phase 1
• A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.CompletedNCT00000704Phase 1
• Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group MembersCompletedNCT00000703Not applicable
• A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) InfectionCompletedNCT00000702Phase 3
• A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)CompletedNCT00000701Phase 1
• A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCPCompletedNCT00000700Phase 3
• A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic PatientsCompletedNCT00000699Phase 1
• A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV DiseaseCompletedNCT00000696Phase 1